Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-P4
2024-519960-42-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of alpelisib in PIK3CA-related overgrowth spectrum (PROS), sponsored by Novartis. Primary endpoint: Confirmed objective radiological response rate. Planned start Oct 2025; status: authorised.
02
Drugs
alpelisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)
Beyond the preview
Go deeper on 2024-519960-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519960-42-00.